Elicera Therapeutics AB (publ) Stock Price

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.